Personalized approaches have dramatically improved outcomes for many patients with non-Hodgkin B-cell lymphomas—blood cancers that arise in immune cells called B cells—yet the same is not true for patients with more rare lymphoma types that originate in immune cells called T cells.

Peripheral T-cell lymphomas comprise diverse blood cancers that have a distinct biology, and survival rates vary widely. Lymphoma specialist ...